Sven E Pålhagen1, Olof Sydow2, Anders Johansson3, Dag Nyholm3, Bjorn Holmberg4, Hakan Widner5, Nil Dizdar6, Jan Linder7, Tove Hauge8, Rasmus Jansson9, Lars Bergmann10, Susanna Kjellander11, Thomas S Marshall10. 1. Department of Neurology, Karolinska University Hospital, Stockholm, Sweden. Electronic address: sven.palhagen@karolinska.se. 2. Department of Neurology, Karolinska University Hospital, Stockholm, Sweden. 3. Department of Neuroscience, Neurology, Uppsala University, Sweden. 4. Department of Clinical Neuroscience, Sahlgrenska University Hospital, Gothenburg, Sweden. 5. Department of Neurology, Skane University Hospital, Lund, Sweden. 6. Department of Neurology and Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden. 7. Department of Neurology, Neurocentre Norrlands University Hospital, Umeå, Sweden. 8. Department of Neurology, Molde Hospital HNR, Molde, Norway. 9. Department of Geriatric Medicine and Rehabilitation, Sundsvall Hospital, Sundsvall, Sweden. 10. AbbVie Inc., USA. 11. AbbVie AB, Sweden.
Abstract
BACKGROUND: Continuous infusion of levodopa-carbidopa intestinal gel (LCIG) can effectively manage motor and non-motor complications in advanced Parkinson's disease (PD). Healthcare costs, quality of life (QoL), effectiveness, and tolerability were assessed in routine care treatment with LCIG. METHODS: The seventy-seven patients enrolled in this prospective, open-label, 3-year study in routine medical care were LCIG-naïve (N = 37), or had previous LCIG treatment for <2 (N = 22), or ≥2 (N = 18) years. Healthcare costs were collected monthly. PD symptoms and QoL were assessed with the Unified Parkinson's Disease Rating Scale (UPDRS), 39-item Parkinson's Disease Questionnaire (PDQ-39), and EuroQoL 5-Dimension Visual Analog Scale (EQ-5D VAS); LCIG dose, safety, and tolerability were monitored. RESULTS: Mean monthly costs per patient (€8226 ± 5952) were similar across cohorts, remained steady during 3-year follow-up, and increased with PD severity and QoL impairment. In LCIG-naïve patients, significant improvements compared to baseline were observed on the UPDRS total score and PDQ-39 summary index score through 18 months (n = 24; UPDRS, p = 0.033; PDQ-39, p = 0.049). Symptom control was maintained during 3-year follow-up in LCIG-experienced cohorts. Small changes in mean daily LCIG dose were observed. Adverse events were common and generally related to the device, procedure, levodopa, or laboratory evaluations. CONCLUSIONS: Costs in LCIG-treated patients were stable over 3 years. LCIG treatment led to significant improvements in motor function and QoL over 18 months in LCIG-naïve patients and no worsening was observed in LCIG-experienced patients over 3 years despite natural PD progression over time. The long-term safety was consistent with the established LCIG profile.
BACKGROUND: Continuous infusion of levodopa-carbidopa intestinal gel (LCIG) can effectively manage motor and non-motor complications in advanced Parkinson's disease (PD). Healthcare costs, quality of life (QoL), effectiveness, and tolerability were assessed in routine care treatment with LCIG. METHODS: The seventy-seven patients enrolled in this prospective, open-label, 3-year study in routine medical care were LCIG-naïve (N = 37), or had previous LCIG treatment for <2 (N = 22), or ≥2 (N = 18) years. Healthcare costs were collected monthly. PD symptoms and QoL were assessed with the Unified Parkinson's Disease Rating Scale (UPDRS), 39-item Parkinson's Disease Questionnaire (PDQ-39), and EuroQoL 5-Dimension Visual Analog Scale (EQ-5D VAS); LCIG dose, safety, and tolerability were monitored. RESULTS: Mean monthly costs per patient (€8226 ± 5952) were similar across cohorts, remained steady during 3-year follow-up, and increased with PD severity and QoL impairment. In LCIG-naïve patients, significant improvements compared to baseline were observed on the UPDRS total score and PDQ-39 summary index score through 18 months (n = 24; UPDRS, p = 0.033; PDQ-39, p = 0.049). Symptom control was maintained during 3-year follow-up in LCIG-experienced cohorts. Small changes in mean daily LCIG dose were observed. Adverse events were common and generally related to the device, procedure, levodopa, or laboratory evaluations. CONCLUSIONS: Costs in LCIG-treated patients were stable over 3 years. LCIG treatment led to significant improvements in motor function and QoL over 18 months in LCIG-naïve patients and no worsening was observed in LCIG-experienced patients over 3 years despite natural PD progression over time. The long-term safety was consistent with the established LCIG profile.
Authors: Maria José Catalán; Angelo Antonini; Matilde Calopa; Ovidiu Băjenaru; Oriol de Fábregues; Adolfo Mínguez-Castellanos; Per Odin; José Manuel García-Moreno; Stephen W Pedersen; Zvezdan Pirtošek; Jaime Kulisevsky Journal: eNeurologicalSci Date: 2017-07-02
Authors: Rejko Krüger; Jochen Klucken; Daniel Weiss; Lars Tönges; Pierre Kolber; Stefan Unterecker; Michael Lorrain; Horst Baas; Thomas Müller; Peter Riederer Journal: J Neural Transm (Vienna) Date: 2017-03-24 Impact factor: 3.575
Authors: Katarzyna Smilowska; Daniel J van Wamelen; Tomasz Pietrzykowski; Alexander Calvano; Carmen Rodriguez-Blazquez; Pablo Martinez-Martin; Per Odin; K Ray Chaudhuri Journal: J Parkinsons Dis Date: 2021 Impact factor: 5.568
Authors: Marianne Udd; Jukka Lyytinen; Johanna Eerola-Rautio; Anu Kenttämies; Outi Lindström; Leena Kylänpää; Eero Pekkonen Journal: Brain Behav Date: 2017-06-05 Impact factor: 2.708